Drug intelligence / Profile preview

fulvestrant + neratinib + trastuzumab

Development stage: Unknown
Lead developer: Puma Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intramuscular, Intravenous

Overview

A triplet combination therapy consisting of fulvestrant (a selective estrogen receptor degrader), neratinib (an irreversible pan-HER tyrosine kinase inhibitor), and trastuzumab (a HER2-targeting monoclonal antibody). This combination has shown efficacy in hormone receptor-positive, HER2-negative metastatic breast cancer harboring HER2 mutations, particularly in patients who have progressed on CDK4/6 inhibitors.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)ER (Estrogen receptor)

Beyond the preview

Go deeper on fulvestrant + neratinib + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fulvestrant + neratinib + trastuzumab.

Explore the full profile